Efficacy and safety of efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis and stage 2-3 fibrosis: a phase 2b, randomised, placebo-controlled study.
- DOI
- 10.1016/s0140-6736(26)02043-x
- Published
- 2026 Nov 9
- Container
- Lancet (London, England)
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s0140-6736-26-02043-x,
title = {Efficacy and safety of efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis and stage 2-3 fibrosis: a phase 2b, randomised, placebo-controlled study.},
author = {Lawitz E and Wong VW and Shankar RR and Francque S and Patel K and Miele L and Abdelmalek MF and Krishnan R and Zhang Z and Lam RLH and Golm G and Marquard J and Da BL and Engel SS and Schattenberg JM and MK-6024 P013 study investigators},
year = {2026},
journal = {Lancet (London, England)},
doi = {10.1016/s0140-6736(26)02043-x},
url = {https://doi.org/10.1016/s0140-6736(26)02043-x}
}RIS
TY - JOUR TI - Efficacy and safety of efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis and stage 2-3 fibrosis: a phase 2b, randomised, placebo-controlled study. AU - Lawitz E AU - Wong VW AU - Shankar RR AU - Francque S AU - Patel K AU - Miele L AU - Abdelmalek MF AU - Krishnan R AU - Zhang Z AU - Lam RLH AU - Golm G AU - Marquard J AU - Da BL AU - Engel SS AU - Schattenberg JM AU - MK-6024 P013 study investigators PY - 2026 JO - Lancet (London, England) DO - 10.1016/s0140-6736(26)02043-x UR - https://doi.org/10.1016/s0140-6736(26)02043-x ER -
APA
E, L., VW, W., RR, S., S, F., K, P., L, M., MF, A., R, K., Z, Z., RLH, L., G, G., J, M., BL, D., SS, E., JM, S., & investigators, M. P. S. (2026). Efficacy and safety of efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis and stage 2-3 fibrosis: a phase 2b, randomised, placebo-controlled study.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)02043-x
Source records
- pubmed · retrieved 2026-11-10T09:09:31.538Z